Amplia Therapeutics Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Amplia Therapeutics.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	15.3%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Jan 13

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Apr 28

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Feb 28

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Jan 06

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Amplia Therapeutics non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

ASX:ATX - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2024	4	-5	-5	-5	N/A
12/31/2023	3	-4	-6	-6	N/A
9/30/2023	2	-4	-6	-6	N/A
6/30/2023	2	-5	-6	-6	N/A
3/31/2023	1	-6	-5	-5	N/A
12/31/2022	2	-6	-5	-5	N/A
9/30/2022	3	-5	-5	-5	N/A
6/30/2022	2	-4	-5	-5	N/A
3/31/2022	2	-4	-4	-4	N/A
12/31/2021	2	-3	-4	-4	N/A
9/30/2021	1	-3	-4	-4	N/A
6/30/2021	1	-3	-4	-4	N/A
3/31/2021	2	-2	-3	-3	N/A
12/31/2020	1	-2	-2	-2	N/A
9/30/2020	1	-2	-2	-2	N/A
6/30/2020	0	-2	-2	-2	N/A
3/31/2020	0	-2	-2	-2	N/A
12/31/2019	0	-2	-2	-2	N/A
9/30/2019	0	-2	-2	-2	N/A
6/30/2019	0	-2	-1	-1	N/A
3/31/2019	0	-2	-1	-1	N/A
12/31/2018	0	-2	-2	-2	N/A
9/30/2018	0	-3	-3	-3	N/A
6/30/2018	0	-3	-3	-3	N/A
3/31/2018	1	-4	-4	-4	N/A
12/31/2017	1	-5	N/A	-5	N/A
9/30/2017	1	-6	N/A	-6	N/A
6/30/2017	2	-7	N/A	-6	N/A
3/31/2017	2	-7	N/A	-6	N/A
12/31/2016	2	-7	N/A	-6	N/A
9/30/2016	3	-6	N/A	-5	N/A
6/30/2016	2	-6	N/A	-5	N/A
3/31/2016	2	-5	N/A	-5	N/A
12/31/2015	2	-5	N/A	-4	N/A
9/30/2015	1	-5	N/A	-3	N/A
6/30/2015	0	-5	N/A	-4	N/A
3/31/2015	N/A	-5	N/A	-4	N/A
6/30/2014	0	-5	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista ATX è superiore al tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di ATX cresceranno più velocemente del mercato Australian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di ATX cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di ATX cresceranno più rapidamente del mercato Australian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di ATX cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ATX è previsto essere elevato tra 3 anni

Amplia Therapeutics Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.9 million.

Amplia Therapeutics Limited, Annual General Meeting, Aug 23, 2024

New minor risk - Shareholder dilution

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

New major risk - Market cap size

Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US

New major risk - Financial position

New major risk - Market cap size

Amplia Therapeutics Limited Announces Chief Financial Officer Changes

New major risk - Market cap size

New major risk - Market cap size

Amplia Therapeutics Limited, Annual General Meeting, Aug 24, 2023

Amplia Receives Grant to Collaborate with CSIRO

Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945

Amplia Therapeutics Limited Appoints Christopher Burns as Managing Director, Effective December 5, 2022

Amplia Therapeutics Limited Announces CEO Changes

Amplia Therapeutics Limited Announces First Patient Recruited to ACCENT Trial in Pancreatic Cancer

Amplia Therapeutics Limited, Annual General Meeting, Aug 25, 2022

Amplia Therapeutics Limited Shows AMP945 Efficacy in Model of Lung Fibrosis

Amplia Therapeutics Limited Receives Second Ethics Clearance for Phase 2 Trial

Amplia Therapeutics Limited Receives Human Research Ethics Committee Approval to Initiate Phase 2 Clinical Trial of Its Focal Adhesion Kinase Inhibitor, AMP945

Amplia Therapeutics Limited Completes Manufacture of AMP945 for Planned Trials

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Non-Executive Director recently bought AU$104k worth of stock

Chief Financial Officer Jeff Carter has left the company

Amplia to Conduct Phase 2 Trial in First-Line Pancreatic Cancer Patients

Non-Executive Director recently bought AU$122k worth of stock

Amplia Therapeutics Limited Announces Results from Successful Phase 1 Clinical Trial of Amp945

Amplia Therapeutics Limited Receives New Data from its Collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research, Sydney

Amplia Therapeutics Limited announced that it expects to receive AUD 3.81455 million in funding from Platinum Investment Management Limited, Blueflag Holdings Pty Ltd, Acorn Capital Limited, and other investors

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Amplia Therapeutics Limited Completes Single Dose Study of AMP945

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Amplia Therapeutics Limited Initiates Multiple Dose Study of AMP945

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

New 90-day high: AU$0.22

Amplia Therapeutics Limited Announces First Human Dose in Phase 1 Clinical Trial of AMP945

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.987791 million.

Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita